Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of STX-721/PFL-721 in EGFR or HER2 exon 20 insertion-mutant advanced non-small cell lung cancer
CTR20263495Phase 2Active
- Sponsor
- Pierre Fabre Laboratories
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of PFL-721 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pierre Fabre Laboratories. Primary endpoints: Objective response rate and Treatment-emergent adverse events / serious adverse events of grade >=2. Started Oct 2023; status: active.
02
Drugs
PFL-721
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20263495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263495.